Contents
Introduction
Ingrid Vandenborre and Caroline Janssens

1 An Economists Perspective on Exploitative Abuse of Dominant Position and Excluding Competitors Through
Kilier Acquisitions
Valérie Meunier, Rameet Sanqha and David Sevy
Compass Lexecon

2 Growing EU and UK Regulatory Interest in ALleged
ExcessivePricing
George Zacharodirnos
Skadden, Arps, Siale, Meaqher & Flom LLP

3 An Economic Outlook on Biosimilar Competition in Europe
Avantika Chowdhury, Adriano Barbera and Sam Carr
Oxera Consultinq LLP

4 PCA Product Denigration Decisions and Their Impact in Europe
Marta Giner Asins and Arnaud Sanz
Norton Pose Fulbright LLP

5 Procedural Issues with Merger Control Across Europe
Miranda Cote, Emrna Ctarke and Julien Haverats
Norton Ros Fulbright LLP

6 Recent Developments in the Ana t.ysis of Life Sciences Mergers
Maria Raptis, Michaet Frese, Julia Zhu and Marta Navarro Hernández
SIadderi, Arps, Siate, Meaaher & Flom LLP

7 A Practitioners Perspective on Cooperative
Agreements in Europe
Niels Christian ErsbølL
Arnold & Porter Kaye Scholer LLP

8 Australia: ACCCs Enforcement and Merger Reform
Approach Could Foreshadow Increased Scrutiny
Elizabeth Avery and Susan Jones
Gilbert + Tobin

9 European Union: Commission Intensifies Merger Review Focus on Pipeline Products and Pay-for-Delay Cases in theSpotlight
Salomé Cisnal de Ugrte, Genevève Michaux, Raphaël Fleischer
and Georgios Symeonidis
King & Spalding LLP

10 Germany and AUstria: Post-Pandemic Coilaboration on the Rise Amid Merger Control Legislation Shifts
Tobias Maier, Martin Bechtotd, Aurelius Freytag and Karin Kõtler
Eversheds Sutherland.

11 Itaty: Antitrust Pioneer Continues to Break Ground on
Theories of Harm
Maria Balestriero, Enzo Marasà, Irene Picciano, Fusa Stefanini
and Claudio Todisco
Portolano Cavalo

12 Switzertand: Regulatory Changes and Mutual Market
Access Problems with European Union set to Alter
Competitive Environment
Philipp E Zurkinden, Bernhard C Lauterhurg Andrea Schütz
and Marino Baldi
Prager Dreifuss AG

13 United Kingdom: a Key Jurisdiction for Competition
Law Complíance
Gustaf Duhs and Jeremy KeLIy
Stevens & Boltor, LLP

14 United States: Trends of Agency Scrutiny on Pharmaceutical Transactions Expected to Shift Amid Rise
In Deal Activity
Andrew Lacy, Arman Oruc, Elliot. Silver and Chartie Stewart
Goodwin Procter LLP

About the Authors
Contributors Contact Detaits